Antinociceptive synergistic effect of spinal mGluR2/3 antagonist and glial cells inhibitor on peripheral inflammation-induced mechanical hypersensitivity.
Metabotropic glutamate receptor (mGluR) 2/3 is distributed in neurons and glial cells in many regions of the nervous system, but its role in nociceptive processing is unclear. In this study, we examined the mRNA expressions of mGluR2 and mGluR3, by real-time RT-PCR, in the spinal cord. We further investigated the possible involvement of mGluR2/3 and mechanisms underlying peripheral inflammatory pain induced by subcutaneous complete Freund's adjuvant (CFA) injection. We demonstrate that compared to the controls, the mRNA expression levels of mGluR2 and mGluR3 were significantly higher 4h after CFA injection. Functionally, blocking mGluR2/3 by their antagonist (2S)-2-amino-2-[(1S, 2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495) alleviated the CFA-induced mechanical allodynia and the inhibitory effects were reversed by mGluR2/3 agonist (2R, 4R)-4-aminopyrrolidine-2,4-dicarboxylate ((2R, 4R)-APDC). In addition, a glial metabolism inhibitor dl-fluorocitric acid barium salt (fluorocitric acid) also inhibited the CFA-induced mechanical allodynia in a dose-dependent manner. Remarkably, simultaneous inhibition of mGluR2/3 and glial metabolism had synergistic effects. The co-administration of LY341495 and fluorocitric acid with minimal dosages produced significant more inhibition than the additive effects by the individual inhibitor alone. In summary, our data suggest that spinal mGluR2/3 contributes to the generation of mechanical allodynia induced by peripheral inflammation. We also suggest that involvement of mGluR2/3 in the communication between glial cells and neurons takes part in the processing of nociceptive information.
Department of Anatomy and K.K. Leung Brain Research Centre, Fourth Military Medical University, Chang-le West Road 169, Xi'an 710032, PR China.
Ting
T
Zhang
Jing
J
Zhang
Juan
J
Shi
Yupeng
Y
Feng
Zhong Sheng
ZS
Sun
Huili
H
Li
D000596:Amino Acids / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D002951:Citrates / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005620:Freund's Adjuvant / Q000008:administration & dosage; D006941:Hyperesthesia / Q000503:physiopathology; D007249:Inflammation / Q000503:physiopathology*; D008297:Male; D009457:Neuroglia / Q000378:metabolism*; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology*; D011392:Proline / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology*; D013116:Spinal Cord / Q000378:metabolism*; D014966:Xanthenes / Q000494:pharmacology
C097299:4-aminopyrrolidine-2,4-dicarboxylic acid; D000596:Amino Acids; D000700:Analgesics; D002951:Citrates; C114624:LY 341495; D018094:Receptors, Metabotropic Glutamate; D014966:Xanthenes; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3; C007744:fluorocitrate; D005620:Freund's Adjuvant; D011392:Proline